TREATING INFLAMMATION WITH SOLUBLE HYBRID FCGAMMA RECEPTORS
First Claim
Patent Images
1. A method of reducing IgG-mediated inflammation in a subject, the method comprising:
- administering to the subject with IgG-mediated inflammation a therapeutically effective amount of a soluble polypeptide comprising amino acid residues 43-310 of SEQ ID NO;
42, amino acid residues 21-286 of SEQ ID NO;
44;
or amino acid residues 21-286 of SEQ ID NO;
46, and wherein the polypeptide is capable of specifically binding the Fc region of IgG.
0 Assignments
0 Petitions
Accused Products
Abstract
Disclosed are soluble hybrid Fcγ receptor (FcγR) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid FcγR polypeptides.
-
Citations
6 Claims
-
1. A method of reducing IgG-mediated inflammation in a subject, the method comprising:
administering to the subject with IgG-mediated inflammation a therapeutically effective amount of a soluble polypeptide comprising amino acid residues 43-310 of SEQ ID NO;
42, amino acid residues 21-286 of SEQ ID NO;
44;
or amino acid residues 21-286 of SEQ ID NO;
46, and wherein the polypeptide is capable of specifically binding the Fc region of IgG.- View Dependent Claims (2)
-
3. A method of treating an IgG-mediated inflammatory disease in a subject, the method comprising:
- administering to the subject a therapeutically effective amount of a soluble polypeptide comprising amino acid residues 43-310 of SEQ ID NO;
42, amino acid residues 21-286 of SEQ ID NO;
44, or amino acid residues 21-286 of SEQ ID NO;
46, and wherein the polypeptide is capable of specifically binding the Fc region of IgG. - View Dependent Claims (4)
- administering to the subject a therapeutically effective amount of a soluble polypeptide comprising amino acid residues 43-310 of SEQ ID NO;
-
5. A method of treating an IgG-mediated inflammatory disease in a subject, the method comprising:
- administering to the subject a therapeutically effective amount of a composition comprising a soluble polypeptide and a pharmaceutically acceptable carrier, wherein the soluble polypeptide comprises amino acid residues 43-310 of SEQ ID NO;
42, amino acid residues 21-286 of SEQ ID NO;
44, or amino acid residues 21-286 of SEQ ID NO;
46, and wherein the polypeptide is capable of specifically binding the Fc region of IgG. - View Dependent Claims (6)
- administering to the subject a therapeutically effective amount of a composition comprising a soluble polypeptide and a pharmaceutically acceptable carrier, wherein the soluble polypeptide comprises amino acid residues 43-310 of SEQ ID NO;
Specification